Sai Life Sciences Limited has released its Monitoring Agency Report for the quarter ended March 31, 2026. The report confirms that the company has fully utilized the proceeds allocated for the repayment of borrowings and general corporate purposes in previous quarters. As of the end of the Q4 FY 2026, a balance of Rs 55.28 million remains, primarily designated for issue-related expenses.
Financial Utilization Summary
The monitoring agency report, prepared by CRISIL Ratings Limited, details the utilization of the Rs 9,500.00 million raised through the company’s Initial Public Offering. As of the quarter ending March 31, 2026, the company has successfully completed the utilization of funds earmarked for debt repayment (Rs 7,200.00 million) and general corporate purposes (Rs 1,898.84 million).
Status of Issue Expenses
The report highlights that the total expenditure incurred for the IPO process stands at Rs 345.88 million against an original provision of Rs 401.16 million. The remaining unutilized amount of Rs 55.28 million is currently held in designated public offer and monitoring bank accounts and fixed deposits, which earned a return of approximately 5.45% per annum during the reported quarter.
Operational Highlights
There have been no deviations from the objects stated in the offer document, and no revisions to the costs were required. The management has confirmed that there is no change in the means of finance, and all prior disclosures remain consistent with the company’s current financial position. No utilization was reported during the quarter, reflecting the near-completion of the IPO-related fund deployment lifecycle.
Source: BSE
